Neil Dahiya

Tagomics Ltd. Partners with Agilent Technologies for Joint Co-Marketing Initiative in Multiomic Profiling

Tagomics Ltd., known for its groundbreaking work in biomarker discovery and diagnostics, has announced a strategic partnership with Agilent Technologies, a key player in genomic tools, to embark on a co-marketing initiative. This collaboration will enable selected clients to access

Tagomics Ltd. Partners with Agilent Technologies for Joint Co-Marketing Initiative in Multiomic Profiling Read More »

Abbott Introduces New Strategies and Collaborations to Boost Diversity in Clinical Trials

Abbott, in the third year marking its substantial Diversity in Clinical Trials campaign, has introduced ‘Advancing Diversity in Clinical Trials,’ a publication offering strategies to enhance diversity within clinical research teams throughout the United States. At the same time, Abbott

Abbott Introduces New Strategies and Collaborations to Boost Diversity in Clinical Trials Read More »

Samsung Biologics Secures Manufacturing Agreements of $668 Million with a European Pharma Firm

Samsung Biologics, a renowned contract development and manufacturing organization (CDMO), has recently forged a series of manufacturing agreements with a pharmaceutical company based in Europe. These newly revealed contracts, valued at over $668 million in total, are set to extend

Samsung Biologics Secures Manufacturing Agreements of $668 Million with a European Pharma Firm Read More »

Merck’s Phase 3 Study Reveals Successful Outcomes for Subcutaneous Pembrolizumab with Berahyaluronidase Alfa

Merck, recognized as MSD outside the United States and Canada, has announced encouraging topline outcomes from the pivotal phase 3 MK-3475A-D77 study. This investigation is analyzing whether the subcutaneous delivery of pembrolizumab—a renowned anti-PD-1 therapy by Merck, commercially known as

Merck’s Phase 3 Study Reveals Successful Outcomes for Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Read More »

Pfizer’s Hympavzi Secures EU Authorization for Treating Severe Hemophilia A and B in Adolescents and Adults Without Inhibitors

Pfizer Inc. has revealed that the European Commission (EC) has authorized the market release of Hympavzi (marstacimab) for the routine prevention of bleeding episodes in individuals aged 12 and older, who weigh at least 35 kg, with severe hemophilia A

Pfizer’s Hympavzi Secures EU Authorization for Treating Severe Hemophilia A and B in Adolescents and Adults Without Inhibitors Read More »

Pharmexcil and Sberbank Explore Rupee-Ruble Payment Solutions to Enhance Indo-Russian Pharmaceutical Trade

In an important step to strengthen economic ties between India and Russia, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and Russia’s largest bank, Sberbank, are in discussions to establish payment methods in Rupee-Ruble bilateral trade. These discussions aim to

Pharmexcil and Sberbank Explore Rupee-Ruble Payment Solutions to Enhance Indo-Russian Pharmaceutical Trade Read More »

Research from Ayush-ICMR Centers Set to Create National Reports for International Promotion of Ayush Remedies: Dr. Kotecha

The Indian Ayush Ministry’s partnerships with prestigious institutions such as the Indian Council of Medical Research (ICMR) aim to bolster the scientific grounds of Ayush treatments and facilitate their global recognition. Each initiative under these collaborations is crafted to enhance

Research from Ayush-ICMR Centers Set to Create National Reports for International Promotion of Ayush Remedies: Dr. Kotecha Read More »

Department of Pharmaceuticals Denies Abbott’s Appeal Against BP Drug Metoprolol Pricing

The Pharmaceuticals Department (DoP) has turned down Abbott Healthcare’s appeal against the pricing cap set by the National Pharmaceutical Pricing Authority (NPPA) for high blood pressure medication metoprolol in its modified release tablet form. This decision follows multiple denials by

Department of Pharmaceuticals Denies Abbott’s Appeal Against BP Drug Metoprolol Pricing Read More »